Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

R Labianca

Showing results (91-100 of 166) with videos related to

Pageof 17
Sort By:
Tumori|June 30, 1990
Quality of care of colorectal cancer patients in general hospitals: diffusion and impact of management guidelinesG Apolone, R Grilli, A A Alexanian, et al.
British Journal of Cancer|February 24, 2001
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancerS Cascinu, F Graziano, S Barni, et al.
British Journal of Cancer|October 17, 2003
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancerF Graziano, D Santini, E Testa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM)S Barni, M Venturini, G D Beretta, et al.
Oncology|March 1, 1993
A cisplatinum-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year resultsM C Locatelli, A D'Antona, R Carcione, et al.
British Journal of Cancer|July 26, 2012
Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studiesM Mandalà, F Grosso, C Vitalini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronR Gralla, M Lichinitser, S Van Der Vegt, et al.
Annals of Surgical Oncology|November 1, 1995
Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapyM Lise, D Nitti, A Marchet, et al.
Journal of Pain and Symptom Management|January 1, 1997
Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative CareM Maltoni, M Pirovano, O Nanni, et al.
Oncology|July 15, 2005
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patientsM Scartozzi, A Sobrero, G Gasparini, et al.
Pageof 17

Showing results (91-100 of 166) with videos related to

Sort By:
Pageof 17
Tumori|June 30, 1990
Quality of care of colorectal cancer patients in general hospitals: diffusion and impact of management guidelinesG Apolone, R Grilli, A A Alexanian, et al.
British Journal of Cancer|February 24, 2001
A phase II study of sequential chemotherapy with docetaxel after the weekly PELF regimen in advanced gastric cancer. A report from the Italian group for the study of digestive tract cancerS Cascinu, F Graziano, S Barni, et al.
British Journal of Cancer|October 17, 2003
A phase II study of weekly cisplatin, 6S-stereoisomer leucovorin and fluorouracil as first-line chemotherapy for elderly patients with advanced gastric cancerF Graziano, D Santini, E Testa, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 27, 2007
Agreement between oncology guidelines and clinical practice in Italy: the 'right' program. A project of the Italian Association of Medical Oncology (AIOM)S Barni, M Venturini, G D Beretta, et al.
Oncology|March 1, 1993
A cisplatinum-cyclophosphamide regimen in advanced ovarian cancer: reporting 5-year resultsM C Locatelli, A D'Antona, R Carcione, et al.
British Journal of Cancer|July 26, 2012
Venous thromboembolism is a relevant and underestimated adverse event in cancer patients treated in phase I studiesM Mandalà, F Grosso, C Vitalini, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 25, 2003
Palonosetron improves prevention of chemotherapy-induced nausea and vomiting following moderately emetogenic chemotherapy: results of a double-blind randomized phase III trial comparing single doses of palonosetron with ondansetronR Gralla, M Lichinitser, S Van Der Vegt, et al.
Annals of Surgical Oncology|November 1, 1995
Prognostic factors in resectable gastric cancer: results of EORTC study no. 40813 on FAM adjuvant chemotherapyM Lise, D Nitti, A Marchet, et al.
Journal of Pain and Symptom Management|January 1, 1997
Biological indices predictive of survival in 519 Italian terminally ill cancer patients. Italian Multicenter Study Group on Palliative CareM Maltoni, M Pirovano, O Nanni, et al.
Oncology|July 15, 2005
The role of 5-fluorouracil (5-FU) reintroduction with irinotecan or oxaliplatin in truly 5-FU-refractory advanced colorectal cancer patientsM Scartozzi, A Sobrero, G Gasparini, et al.
Pageof 17